StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals ( NASDAQ:CYCC – Free Report ) in a research report sent to investors on Tuesday morning. The firm issued a sell rating on the biotechnology company's stock. Cyclacel Pharmaceuticals Stock Performance NASDAQ:CYCC opened at $0.59 on Tuesday. The company has a fifty day moving average of $0.63 and a two-hundred day moving average of $0.71. The stock has a market capitalization of $7.35 million, a PE ratio of -0.30 and a beta of 1.

https://www.dailypolitical.com/2023/07/15/cyclacel-pharmaceuticals-nasdaqcycc-now-covered-by-stocknews-com.html

#dailypolitical